| MeSH term | MeSH ID | Detail |
|---|---|---|
| Asthenia | D001247 | 5 associated lipids |
| Body Weight | D001835 | 333 associated lipids |
| Brain Diseases | D001927 | 27 associated lipids |
| Breast Neoplasms | D001943 | 24 associated lipids |
| Bronchial Spasm | D001986 | 18 associated lipids |
| Colonic Neoplasms | D003110 | 161 associated lipids |
| Hyperplasia | D006965 | 34 associated lipids |
| Hypopharyngeal Neoplasms | D007012 | 1 associated lipids |
| Leukemia | D007938 | 74 associated lipids |
| Leukemia P388 | D007941 | 43 associated lipids |
MAYTANSINE
MAYTANSINE is a lipid of Polyketides (PK) class. Maytansine is associated with abnormalities such as Myelosuppression and BOSLEY-SALIH-ALORAINY SYNDROME. The involved functions are known as Mutation, Agent, Polymerization, Cell Cycle Arrest and Drug Kinetics. Maytansine often locates in Cytoplasm, Hepatic, Lysosomes, Cell surface and Microtubules. The associated genes with MAYTANSINE are ABCB1 gene, HM13 gene, CNN1 gene, CYP2C8 gene and CYP2D6 gene. The related lipids are Valerates. The related experimental models are Xenograft Model.
Cross Reference
Introduction
To understand associated biological information of MAYTANSINE, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with MAYTANSINE?
MAYTANSINE is suspected in Myelosuppression, BOSLEY-SALIH-ALORAINY SYNDROME and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with MAYTANSINE
PubChem Associated disorders and diseases
What pathways are associated with MAYTANSINE
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with MAYTANSINE?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with MAYTANSINE?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with MAYTANSINE?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with MAYTANSINE?
Related references are published most in these journals:
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with MAYTANSINE?
Xenograft Model
Xenograft Model are used in the study 'IMGN853, a Folate Receptor-α (FRα)-Targeting Antibody-Drug Conjugate, Exhibits Potent Targeted Antitumor Activity against FRα-Expressing Tumors.' (Ab O et al., 2015).
Related references are published most in these journals:
| Model | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
NCBI Entrez Crosslinks
All references with MAYTANSINE
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Riechelmann H et al. | Phase I trial with the CD44v6-targeting immunoconjugate bivatuzumab mertansine in head and neck squamous cell carcinoma. | 2008 | Oral Oncol. | pmid:18203652 |
| Montero JC et al. | Identification of therapeutic targets in ovarian cancer through active tyrosine kinase profiling. | 2015 | Oncotarget | pmid:26336133 |
| Nonagase Y et al. | Heregulin-expressing HER2-positive breast and gastric cancer exhibited heterogeneous susceptibility to the anti-HER2 agents lapatinib, trastuzumab and T-DM1. | 2016 | Oncotarget | pmid:27768588 |
| Raja SM et al. | Marked enhancement of lysosomal targeting and efficacy of ErbB2-targeted drug delivery by HSP90 inhibition. | 2016 | Oncotarget | pmid:26859680 |
| Pegram M | Treatment combinations for HER2-positive breast cancer. | 2013 | Oncology (Williston Park, N.Y.) | pmid:23781688 |
| Ranson M and Sliwkowski MX | Perspectives on anti-HER monoclonal antibodies. | 2002 | Oncology | pmid:12422051 |
| Mujagić H and Mujagić Z | Detection of pleiotropic drug resistance by the rapid immunofluorescence assay of drug effects on the cell skeleton. | 1991 | Oncology | pmid:2023698 |
| Lynce F et al. | SAFE-HEaRt: Rationale and Design of a Pilot Study Investigating Cardiac Safety of HER2 Targeted Therapy in Patients with HER2-Positive Breast Cancer and Reduced Left Ventricular Function. | 2017 | Oncologist | pmid:28314836 |
| Kan S et al. | Gemcitabine treatment enhances HER2 expression in low HER2-expressing breast cancer cells and enhances the antitumor effects of trastuzumab emtansine. | 2015 | Oncol. Rep. | pmid:25976081 |
| Yamashita-Kashima Y et al. | Enhanced antitumor activity of trastuzumab emtansine (T-DM1) in combination with pertuzumab in a HER2-positive gastric cancer model. | 2013 | Oncol. Rep. | pmid:23783223 |
| Hussar DA | New drugs 2014, part 3. | 2014 | Nursing | pmid:25153167 |
| Johnson MS | The top 10 drug trends right now. | 2013 | Nurs Manage | pmid:23764906 |
| Carlson JA et al. | Trastuzumab emtansine and stereotactic radiosurgery: an unexpected increase in clinically significant brain edema. | 2014 | Neuro-oncology | pmid:24497407 |
| Ponte JF et al. | Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, Potentiates the Activity of Standard of Care Therapeutics in Ovarian Cancer Models. | 2016 | Neoplasia | pmid:27889646 |
| Wright J | Nanotechnology: Deliver on a promise. | 2014 | Nature | pmid:24870822 |
| Higashide E et al. | Ansamitocin, a group of novel maytansinoid antibiotics with antitumour properties from Nocardia. | 1977 Dec 22-29 | Nature | pmid:593392 |
| Eisenstein M | Medicine: Eyes on the target. | 2015 | Nature | pmid:26580159 |
| Wei GZ et al. | A new antitumour ansamitocin from Actinosynnema pretiosum. | 2010 | Nat. Prod. Res. | pmid:20582809 |
| Siyu-Mao et al. | Two novel ansamitocin analogs from Actinosynnema pretiosum. | 2013 | Nat. Prod. Res. | pmid:23061718 |
| DeFrancesco L | Drug pipeline: 1Q13. | 2013 | Nat. Biotechnol. | pmid:23752422 |